Feb 07th 2013 - Edison Investment Research today published a report on Morphosys entitled "A Quarter To Remember". In summary, the report says:
The presentation of data and completion of deals by MorphoSys marked Q412 as an important time for the company. Data presented on MOR103, MOR208 and a product related to MOR202 indicated the potential of its proprietary pipeline. The amendments to its long-term collaboration with Novartis are expected to lead to new discovery alliances and extra resources for its proprietary pipeline. The sale of its AbD Serotec division for a net consideration of €48m has also generated additional funds for MorphoSys to invest in its own products. The next significant event that could occur is the partnering of MOR103. We have raised our valuation to €804m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
